Depression Therapeutics Market Worldwide Top Players Revenue Analysis of Pfizer, Inc., Eli Lilly and Company, AstraZeneca, Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda

Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. The global depression therapeutics market was valued at US$ 12,406.8 million in 2016 and is expected to witness a CAGR of 2.1% over the forecast period (2017–2025).

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1307

Rising prevalence of mental disorders such as depression and anxiety is expected to boost growth of the depression therapeutics market over the forecast period

Mental disorders such as major depressive disorder, anxiety, and associated co-morbidities have high global prevalence. According to the World Health Organization (WHO), in 2017, around 300 million people are estimated to be affected with depression, globally. Furthermore, WHO passed a World Health Assembly resolution in 2013, to address mental disorders in a comprehensive and coordinated manner and has covered depression under its Mental Health Gap Action Program. According to Anxiety & Depression Association of America (ADAA), major depressive disorder is the leading cause of disability in the U.S., among people aged

Low costs of antidepressant medication along with lack of affordable alternative therapies are expected to boost growth of the global depression therapeutics market over the forecast period

Mental disorders such as depression and anxiety are treated either with medication or psychotherapy, which involves cognitive behavioral therapy (CBT). According to American Psychiatric Association, 2017, although both the therapies exhibit similar levels of effectiveness with 30% to 40% remission rates, the cost-effectiveness of these therapies plays an important role.

Depression Therapeutics Market Competitive Landscape

Some major players operating in the global depression therapeutics market are Pfizer, Inc., Eli Lilly and Company, AstraZeneca, Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd, and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/1307

Detailed Segmentation:

• Global Depression Therapeutics Market, By Drug Type:

o Selective Serotonin Reuptake Inhibitors (SSRIs)
o Selective Norepinephrine Reuptake Inhibitors (SNRIs)
o Others

• Global Depression Therapeutics Market, By Distribution Channel:

o Hospital Pharmacies
o Online Pharmacies
o Retail Pharmacies

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.